PROF Profound Medical (PROF) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001628808
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
18
13F, latest reported quarter
Profound Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Profound Medical Corp. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 15, 2025.
- The trade is 2.0% of the 587,089 shares held after it.
- No other insider bought within 30 days.
- 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Menawat Arun Swarup bought about $56.9K of PROF on May 16, 2025, the largest insider purchase at the company on our record; 18 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.7% of the 575,062 shares held after it.
- No other insider bought within 30 days.
- 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Menawat Arun Swarup bought about $43.3K of PROF on May 15, 2025, the largest insider purchase at the company on our record; 18 funds added in the latest 13F quarter.2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
18 funds bought in last quarter
below 75% of Medical Devices
Revenue
+50.7% year over year
more than 86% of Medical Devices
Margin
-264.4% net margin
below 87% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.2% of the float short (float per yahoo 2026-10-26) · 11.9 days to cover · settled 2026-09-30
more than 56% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PROF
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.6%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PROF: institutional holders (13F)
13F holdings, latest reported quarter
2,370,000 sh
$15.8M
1,960,074 sh
$13.0M
1,199,564 sh
$8.0M
1,114,967 sh
$7.4M
962,186 sh
$6.4M
Congress trades in PROF
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PROF planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PROF mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Royce Micro-Cap Fund
$2.3M position · as of 2026-06-30
0.5%
Royce Capital Fund - Micro-Cap Portfolio
$750.5K position · as of 2026-06-30
0.5%
First Eagle Small Cap Opportunity Fund
$2.9M position · as of 2026-07-31
0.1%
The Canadian Small Company Series
$33.9K position · as of 2026-07-31
0.0%
Fidelity Nasdaq Composite Index Fund
$155.8K position · as of 2026-05-31
0.0%
Dimensional International Small Cap ETF
$6.7K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 18 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PROF financials
Revenue growth
+50.7%
XBRL, annual
Net margin
-264.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$19.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PROF
| FY Dec 2025 | $16.1M |
| FY Dec 2024 | $10.7M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $2.5M |
| Mar 2026 | $5.3M |
| Dec 2025 | $6.0M |
| Sep 2025 | $5.3M |
| Jun 2025 | $2.2M |
| Mar 2025 | $2.6M |
| Dec 2024 | $4.2M |
| Sep 2024 | $2.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-171.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PROF
| FY Dec 2025 | -264.4% |
| FY Dec 2024 | -260.4% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -384.2% |
| Mar 2026 | -132.2% |
| Dec 2025 | -136.8% |
| Sep 2025 | -150.8% |
| Jun 2025 | -709.9% |
| Mar 2025 | -409.2% |
| Dec 2024 | -118.5% |
| Sep 2024 | -330.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM PROF
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.09x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity PROF
| FY Dec 2025 | 0.14x |
| FY Dec 2024 | 0.08x |
| FY Dec 2023 | 0.23x |
| FY Dec 2022 | 0.14x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.09x |
| Mar 2026 | 0.08x |
| Dec 2025 | 0.14x |
| Sep 2025 | 0.14x |
| Jun 2025 | 0.16x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.08x |
| Sep 2024 | 0.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-8.01x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt PROF
| FY Dec 2025 | -4.26x |
| FY Dec 2024 | -5.03x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -8.01x |
| Mar 2026 | -8.55x |
| Dec 2025 | -4.26x |
| Sep 2025 | -8.38x |
| Jun 2025 | -5.60x |
| Mar 2025 | -4.37x |
| Dec 2024 | -5.03x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-73.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PROF
| FY Dec 2025 | -67.1% |
| FY Dec 2024 | -60.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -73.5% |
| Mar 2026 | -70.6% |
| Dec 2025 | -67.1% |
| Sep 2025 | -125.2% |
| Jun 2025 | -104.2% |
| Mar 2025 | -66.4% |
| Dec 2024 | -60.7% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-58.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PROF
| FY Dec 2025 | -57.6% |
| FY Dec 2024 | -48.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -58.4% |
| Mar 2026 | -57.9% |
| Dec 2025 | -57.6% |
| Sep 2025 | -93.0% |
| Jun 2025 | -82.0% |
| Mar 2025 | -52.5% |
| Dec 2024 | -48.7% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital PROF
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-72.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PROF
| FY Dec 2025 | -61.1% |
| FY Dec 2024 | -65.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -72.8% |
| Mar 2026 | -64.4% |
| Dec 2025 | -61.1% |
| Sep 2025 | -130.5% |
| Jun 2025 | -96.3% |
| Mar 2025 | -65.4% |
| Dec 2024 | -65.3% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
12.09x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PROF
| FY Dec 2025 | 21.27x |
| FY Dec 2024 | 6.77x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 14.46x |
| Mar 2026 | 32.40x |
| Dec 2025 | 21.27x |
| Sep 2025 | 17.46x |
| Jun 2025 | 14.75x |
| Mar 2025 | 4.85x |
| Dec 2024 | 6.77x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$169.4M
market value at close 2026-10-23 on 2026-08-06 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value PROF
| FY Dec 2025 | $186.9M |
| FY Dec 2024 | $110.2M |
| FY Dec 2023 | $162.3M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $207.9M |
| Mar 2026 | $189.4M |
| Dec 2025 | $186.9M |
| Sep 2025 | $126.6M |
| Jun 2025 | $148.3M |
| Mar 2025 | $134.6M |
| Dec 2024 | $110.2M |
| Sep 2024 | $151.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield PROF
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.81x
P/E over trailing EPS growth of 15%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing PROF
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.96x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $16.1M | $10.7M | $7.2M | n/a |
| Gross profit | $11.4M | $7.0M | $4.3M | $3.0M |
| Operating income | -$41.3M | -$33.1M | -$28.7M | n/a |
| Net income | -$42.6M | -$27.8M | -$28.3M | -$28.7M |
| EPS (diluted) | 1.41 | 1.12 | 1.34 | n/a |
| Operating cash flow | -$38.2M | -$23.5M | -$22.6M | n/a |
| Cash | $59.7M | $54.9M | $26.2M | n/a |
| Long-term debt | $4.5M | $2.9M | $5.0M | $7.2M |
SEC XBRL, fiscal years, as known on 2026-10-27
PROF Stock Sonar score 5/7 axes
Find similar shapesComparePROF ranks highest on growth (86th percentile) and risk and compliance (66th), and lowest on institutional and government (25th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
